Featured Publications
Effect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure
Clarke JD, Riello R, Allen LA, Psotka MA, Teerlink JR, Lindenfeld J, Desai NR, Ahmad T. Effect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure. Circulation Heart Failure 2021, 14: e007759. PMID: 33530705, DOI: 10.1161/circheartfailure.120.007759.Peer-Reviewed Original ResearchMeSH KeywordsCardiotonic AgentsFunctional StatusHealth StatusHeart FailureHumansPatient Reported Outcome MeasuresQuality of LifeRandomized Controlled Trials as TopicStroke VolumeConceptsEnd-stage heart failureReduced ejection fractionHealth-related qualityPatient-reported health statusEffect of inotropesHeart failureHealth status domainsEjection fractionHealth statusFunctional statusPositive inotropesStatus domainsAvailable clinical trial dataMorbidity/mortalityPopulation of patientsPatient-centered outcomesHealth status outcomesClinical trial dataFunctional capacity changesQuantity of lifeWeb of ScienceInotrope therapyInotrope useCalcium sensitizerSurvival benefit
2018
The use of betrixaban for extended prophylaxis of venous thromboembolism events in hospitalized, high-risk patients.
Dobesh PP, Ahuja T, Davis GA, Fatodu H, Francis WH, Hull FP, Johnson GL, Lenchus JD, Lenoir JG, McPherson C, Nemeth J, Riello RJ. The use of betrixaban for extended prophylaxis of venous thromboembolism events in hospitalized, high-risk patients. The American Journal Of Managed Care 2018, 24: s475-s482. PMID: 30452199.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedBenzamidesFactor Xa InhibitorsFemaleHealth Care CostsHospitalizationHumansMalePrimary PreventionPyridinesRandomized Controlled Trials as TopicRisk FactorsUnited StatesVenous Thromboembolism